Pediatrics

Often an indicator of fibrosis or damage to the heart, late gadolinium enhancement was found to be unaffected by the administration of intravenous immunoglobulin (IVIG) in pediatric patients with myocarditis.

Prescription stimulant dispensing was greatly impacted by the COVID-19 pandemic and drug shortages.

Atopic dermatitis significantly impacts quality of life, and requires personalized management through trigger identification, skin barrier maintenance, and a range of topical, oral, and biologic therapies to reduce symptoms and prevent flare-ups.

Apitegromab is a muscle-targeted therapy for improvement of motor function in individuals with spinal muscular atrophy.

Hypertrophic cardiomyopathy is caused by abnormal genes in the heart muscle, causing the left ventricle to become thicker and effecting blood flow.

Children and adults with cancer have differing immune system responses, mutational burdens, and tissue microenvironments.

This follows the approval of everolimus tablets for patients aged 1 and older in January 2025.

Biosimilar use is not linked to an increased risk of treatment failure among pediatric patients with inflammatory bowel disease (IBD).

Admissions to the hospital for fever were reduced in pediatric patients with medium-risk ALL receiving intravenous immunoglobulin, a potentially useful finding to help prevent infections in vulnerable patients.

These new regulatory developments put CUTX-101 on track to become the first FDA-approved treatment for patients with Menkes disease.

This association was also observed in siblings of children with autism spectrum disorder.

Management of acute otitis media in children involves evidence-based antibiotic prescribing.

Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.

Study results show that the updated BNT162b2 XBB vaccine is effective in preventing hospitalizations or emergency department visits associated with COVID-19 complications.

Factors associated with intravenous immunoglobulin (IVIG)-related adverse events include older age, dehydration, and administration of multiple IVIG infusions.

Setmelanotide is indicated to reduce excess body weight and maintain weight reduction long-term for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome.

The approval makes remestemcel-L-rknd the first approved mesenchymal stromal cell in the United States.

Clesrovimab would be the first and only single dose immunization indicated for infants regardless of weight, aimed to protect against their first RSV season.

Ultra-processed food consumption fuels the rising rates of childhood obesity, diabetes, and liver disease, highlighting opportunities for pharmacist intervention.

The decision is based on positive results from the CAHtalyst trials, which both met their primary and secondary end points.

The authors note that routine screening in patients with primary ciliary dyskinesia to help identify undiagnosed asthma.

The pumps can now be used to treat pediatric patients who have symptomatic acute decompensated heart failure and cardiogenic shock.

The authors found high exposure to butylparaben and low exposure to 4-nonylphenol during pregnancy were risk factors for asthma development in children at 4 years of age.

Children born moderate to late preterm also showed more behavior difficulties compared with those born early term or later.

The treatment is a type IA prodrug of dexamethasone that targets CD206+ macrophages.